[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 2006

Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease

Author Affiliations

Author Affiliations: Division of Neonatology, Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock (Dr ElHassan); RAND Corp, Pittsburgh, Pa (Drs Sorbero and Dick); and Divisions of Infectious Disease (Dr Hall) and Neonatology (Dr Stevens), Department of Pediatrics, Strong Children's Research Center, Rochester, NY.

Arch Pediatr Adolesc Med. 2006;160(10):1070-1076. doi:10.1001/archpedi.160.10.1070

Objectives  To evaluate the cost-effectiveness of palivizumab as respiratory syncytial virus prophylaxis in premature infants without chronic lung disease and to evaluate the impact on cost-effectiveness of a potential reduction in risk of asthma following respiratory syncytial virus infection among infants receiving palivizumab.

Design  Two decision analytic models were designed, one with and the other without accounting for increased risk of asthma following respiratory syncytial virus infection.

Setting  A hypothetical community or university hospital.

Participants  Hypothetical cohorts of infants without chronic lung disease born at 26 to 32 weeks' gestation.

Interventions  Palivizumab prophylaxis vs no prophylaxis.

Main Outcome Measures  Expected costs and incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year.

Results  The expected costs were higher for palivizumab prophylaxis as compared with no prophylaxis. The incremental cost-effectiveness ratios were high for all gestations and are not considered cost-effective by today's standards (<$200 000 per quality-adjusted life-year). Both models were sensitive to variation in the cost of palivizumab. The model that included asthma was sensitive to variation in quality of life for children with asthma. In instances where asthma was considered severe with profound worsening in quality of life compared with life without asthma, some infants had an incremental cost per quality-adjusted life-year that was less than $200 000.

Conclusions  Our model supports implementing more restrictive guidelines for palivizumab prophylaxis. Palivizumab was cost-effective for some infants in an analysis that accounted for increased risk of severe asthma following respiratory syncytial virus infection.